1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
The Pathway to Prevention (P2P) for ME/CFS: A Dangerous Process
Gabby Klein gives an overview of the P2P process, shedding light on the pitfalls with advice as to what we can do in protest ...
Discuss the article on the Forums.

Blisibimod for B-Cell Mediated Autoimmune Disease

Discussion in 'Other Health News and Research' started by merylg, Dec 4, 2011.

  1. merylg

    merylg Senior Member

    Messages:
    764
    Likes:
    493
    Sydney, NSW, Australia
    http://www.bioportfolio.com/news/ar...nterim-B-cell-Analysis-Of-Pearl-sc-Study.html

    "About B-Cell Activating Factor (BAFF) and blisibimod

    BAFF has been associated with a wide range of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications."

See more popular forum discussions.

Share This Page